Special Issue "Uremic Toxins"

Guest Editor
Prof. Dr. Joachim Jankowski
Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Medizinische Klinik IV, Hindenburgdamm 30, 12200 Berlin, Germany
E-Mail: joachim.jankowski@charite.de
Phone: +49 30 450 525567
Fax: +49 30 450 525923

Dear Colleagues,

Uremia is a clinical syndrome associated with fluid, electrolyte, and hormone imbalances and metabolic abnormalities, which develop in parallel with deterioration of renal function. The term uremia, which literally means urine in the blood, was first used by Piorry to describe the clinical condition associated with renal failure [1].Uremia is a medical disorder characterized by excessive waste products and urea, which is a waste product of urine, in the blood. As chronic renal failure progresses, a gradual dose-dependent dysfunction of most organ systems occurs [2]. This ultimately results in the malfunctioning of the entire body, and as symptoms become more and more prominent, survival and quality of life can only be maintained by replacing kidney function by dialysis or transplantation.

Currently, chronic renal failure as well as uremia is legitimately considered as a major public-health problem. Since only a part of chronic renal failure patients progress to uremia and on the other hand the therapy of uremia is complex and expensive, (A) identification of mediators of chronic renal failure and uremia using molecular, proteomic, metabolomic, genomic and functional genomics studies, (B) identification of the underlying mechanisms of chronic renal failure and uremia, (C) validation of biomarkers for detecting chronic renal failure patients at risk of progression and (D) development of appropriate medical responses (new drug targets and/or new treatment strategies) are of great importance both for the prognosis and early intervention of renal failure patients.

Therefore, the aim of this special issue "Uremic Toxins" is to make a contribution to the clarification of the mechanisms of uremia, and to develop new therapeutic approaches.

Prof. Dr. Joachim Jankowski
Guest Editor

References

1. Piorry, P.; l'Heritier, D. Traite des Alterations du Sang; Bury & JB Bailliere: Paris, France, 1840.
2. Vanholder, R.; De Smet, R. Pathophysiologic effects of uremic retention solutes. J. Am. Soc. Nephrol. 1999, 10, 1815–1823.

Submission

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Toxins is an international peer-reviewed Open Access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 800 CHF (Swiss Francs).

• chronic renal failure
• uremic syndrome
• retention solutes
• uremic toxins
• kidney function
• cardiovascular diseases
• glomerular filtration rate
• uremia